DrugPatentWatch Database Preview
VIZIMPRO Drug Profile
Which patents cover Vizimpro, and when can generic versions of Vizimpro launch?
Vizimpro is a drug marketed by Pfizer Inc and is included in one NDA. There are two patents protecting this drug.
This drug has fifty patent family members in forty-two countries.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this compound. Additional details are available on the dacomitinib profile page.
Summary for VIZIMPRO
| International Patents: | 50 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 67 |
| Clinical Trials: | 1 |
| Patent Applications: | 2 |
| Drug Prices: | Drug price information for VIZIMPRO |
| DailyMed Link: | VIZIMPRO at DailyMed |
Generic Entry Opportunity Date for VIZIMPRO
Generic Entry Date for VIZIMPRO*:
Constraining patent/regulatory exclusivity:
FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIZIMPRO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 2 |
| National Cancer Centre, Singapore | Phase 2 |
Synonyms for VIZIMPRO
| (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide |
| (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide |
| (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide |
| (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide |
| (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide |
| (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide |
| 1110813-31-4 |
| 1110813-31-4 pound not PF 299804 pound not PF-299804 |
| 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)- |
| 2XJX250C20 |
| AB0035896 |
| ABP000126 |
| AC-25915 |
| AKOS025401818 |
| AOB87383 |
| AOB87735 |
| BC261945 |
| BCP02530 |
| BDBM112499 |
| C24H25ClFN5O2 |
| CHEBI:132268 |
| CHEBI:91466 |
| CHEMBL2110732 |
| CS-0500 |
| D09883 |
| D5450 |
| Dacomitinib |
| Dacomitinib (INN) |
| Dacomitinib (PF299804, PF-00299804) |
| Dacomitinib (PF299804, PF299) |
| Dacomitinib (PF299804) |
| Dacomitinib [USAN:INN] |
| Dacomitinib anhydrous |
| Dacomitinib, PF299804 |
| dacomitinibum |
| DB11963 |
| DTXSID50149493 |
| EX-A030 |
| GTPL7422 |
| HY-13272 |
| J-500784 |
| MFCD19443734 |
| MLS006011275 |
| NCGC00263185-09 |
| PF 00299804 |
| PF 00299804-03 |
| PF-00299804 |
| PF-00299804 dacomitinib |
| PF-00299804-03 |
| PF-299 |
| PF-299804 |
| PF-299804 (Dacomitinib PF-00299804) |
| pf00299804 |
| PF299 |
| PF299804 |
| PF299804|||PF299 |
| Q-4059 |
| QCR-174 |
| RL00451 |
| s2727 |
| SB21754 |
| SC-94589 |
| SMR004703025 |
| SW219155-1 |
| UNII-2XJX250C20 |
| US8623883, No. 2 |
| Y0338 |
| ZINC72266312 |
US Patents and Regulatory Information for VIZIMPRO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | VIZIMPRO | dacomitinib | TABLET;ORAL | 211288-001 | Sep 27, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | VIZIMPRO | dacomitinib | TABLET;ORAL | 211288-002 | Sep 27, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | VIZIMPRO | dacomitinib | TABLET;ORAL | 211288-001 | Sep 27, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VIZIMPRO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Peru | 02152006 | Start Trial |
| Slovenia | 1746999 | Start Trial |
| New Zealand | 550796 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VIZIMPRO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1746999 | 301004 | Netherlands | Start Trial | PRODUCT NAME: DACOMITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, SOLVAAT OF HYDRAAT ERVAN, IN HET BIJZONDER DACOMITINIB MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/19/1354 20190404 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
